Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8800042 | 0.89 | CA12 (0.50) | TSHRRAB9AGABRG2GABRB3GABRA5 | |
| SCHEMBL10532781 | 0.84 | KDM4E (0.49) | RAB9AMAPTCASP3SENP8SENP7 | |
| SCHEMBL7150692 | 0.81 | KMO (0.50) | TSHRRAB9AEGFRCASP3SENP8 | |
| SCHEMBL1312009 | 0.79 | MAPT (0.54) | TSHRMAPTCA12CA1CA2 | |
| SCHEMBL7392508 | 0.79 | GPR17 (0.47) | TSHRRAB9AGABRG2GABRB3GABRA5 | |
| SCHEMBL7708767 | 0.78 | GABRG2 (0.49) | TSHRRAB9AGABRG2GABRB3GABRA5 | |
| SCHEMBL6642630 | 0.75 | TSHR (0.53) | TSHRRAB9AEGFRMAPTCASP3 | |
| SCHEMBL27878777 | 0.75 | TSHR (0.68) | TSHRRAB9AEGFRGABRG2GABRB3 | |
| SCHEMBL8729131 | 0.75 | TSHR (0.50) | TSHRRAB9AMAPTMEN1KMT2A | |
| SCHEMBL4628388 | 0.75 | KDM4E (0.50) | TSHRRAB9AMAPTL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202880-B2 | 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-7632844-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH | 2008-12-25 | — | — | US | disclosed |
| US-7423046-B2 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | NYCOMED GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7329676-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20070259909-A1 | Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1536798-B1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1539164-B1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| EP-1725532-A1 | NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
| US-20050239817-A1 | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALTANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005085203-A1 | NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| EP-1539164-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1536798-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004019945-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019944-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239817-A1 | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | TSHR 2061/4885RAB9A 1089/4885EGFR 4250/4885 |
| US-20070259909-A1 | Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE4D | TSHR 3296/4885RAB9A 941/4885EGFR 3582/4885 |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | PDE4A, PDE4B, PDE3A | TSHR 2061/4885RAB9A 1089/4885EGFR 4250/4885 |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | TSHR 1985/4885RAB9A 1028/4885EGFR 4235/4885 |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | PDE4A, PDE4B, PDE3A | TSHR 2004/4885RAB9A 975/4885EGFR 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.